Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Q32 Bio (Nasdaq: QTTB) will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 12:45 p.m. ET. A live webcast will be available on the company’s Events and Presentations page, with an archived replay accessible for 90 days.

News Market Reaction – QTTB

-7.29%

16 alerts

-7.29% Session close to close

-14.5% Trough in 26 hr 28 min

$82.66M Market Cap

0.6x Rel. Volume

In the Apr 8 session, QTTB declined 7.29%, reflecting a notable negative market reaction. Argus tracked a trough of -14.5% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -7.3% in the session following this news. A negative reaction despite neutral confer...

Analysis

The stock moved -7.3% in the session following this news. A negative reaction despite neutral conference news fits a pattern where even fundamentally positive updates sometimes coincided with declines, such as the -9.05% move after a prior earnings and clinical update. Historically, financing steps and tax-related insider sales also influenced sentiment. Sustained weakness following similar announcements could reflect sensitivity to execution risks and the waiting period before mid-2026 clinical readouts.

Key Figures

Conference time: 12:45 p.m. E.T. Conference date: April 15, 2026 Conference edition: 25th Annual +1 more

4 metrics

Conference time 12:45 p.m. E.T. Time of Needham conference fireside chat on April 15, 2026

Conference date April 15, 2026 Date of Q32 Bio presentation at Needham Virtual Healthcare Conference

Conference edition 25th Annual Edition of the Needham Virtual Healthcare Conference

Replay availability 90 days Archived webcast replay duration after the event

Historical Context

5 past events · Latest: Mar 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 10	Earnings and update	Positive	+17.4%	Reported Q4 2025 results, cash runway to Q4 2027 and trial progress.
Feb 18	Conference appearance	Neutral	-5.4%	Announced fireside chat participation at Oppenheimer healthcare conference.
Feb 17	Capital raising	Negative	+9.7%	Announced $10.5M registered direct offering to fund operations and trials.
Dec 01	Asset sale	Positive	+74.4%	Sold ADX-097 for $12M near term plus milestones and royalties.
Nov 13	Earnings and trial	Positive	-9.1%	Reported Q3 2025 results and completion of enrollment in SIGNAL-AA Part B.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news often led to strong moves, with generally positive fundamental updates but mixed price alignment.

Recent Company History

Over the last several months, Q32 Bio has reported multiple value-driving events. Earnings and 8-K filings highlighted a swing to profitability, collaboration revenue, and cash of $48.3M plus a $10.5M direct offering, extending runway into late 2027. The company completed enrollment of 33 patients in the SIGNAL-AA Part B trial with topline data expected mid-2026. Asset monetization of ADX-097 brought upfront and milestone potential and triggered a 74.43% one-day gain. Conference participation headlines have produced smaller, mixed price reactions, similar in nature to the current Needham conference update.

Key Terms

alopecia areata, autoimmune

2 terms

alopecia areata medical

"developing innovative therapies for alopecia areata (AA) and other autoimmune..."

Alopecia areata is an autoimmune condition in which the body's immune system mistakenly attacks hair follicles, causing round patches of hair loss on the scalp or body; severity ranges from small spots to widespread baldness. Investors watch it because successful treatments, clinical trial results, regulatory approvals, or shifts in prevalence can create or shrink markets for drugs and therapies, affecting the value of companies developing remedies—think of it as demand risk and regulatory risk for hair-loss products.

autoimmune medical

"alopecia areata (AA) and other autoimmune and inflammatory diseases, today..."

An autoimmune condition is when the body’s natural defense system mistakenly attacks healthy tissues, like a security guard that can’t tell residents from intruders. For investors, autoimmune diseases matter because they create long-term treatment needs, ongoing healthcare costs, and large markets for drugs, diagnostics, and devices; progress or setbacks in therapies, clinical trials, or approvals can strongly affect the value of companies working in this area.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 12:45 p.m. E.T. on Wednesday, April 15, 2026 at the 25^th Annual Needham Virtual Healthcare Conference.

A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. An archived replay will be available for 90 days following the event.

About Q32 Bio

Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata¹, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.

For more information, visit www.Q32Bio.com.

¹National Alopecia Areata Foundation

Availability of Other Information About Q32 Bio

Investors and others should note that Q32 Bio communicates with its investors and the public using its website www.Q32Bio.com, including, but not limited to, Q32 Bio's disclosures, investor presentations and FAQs, Securities and Exchange Commission (the "SEC") filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that Q32 Bio posts on its website or on X or LinkedIn could be deemed to be material information. As a result, Q32 Bio encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of Q32 Bio's website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. 

Contacts:

Investors: Brendan Burns
Argot Partners
212.600.1902
Q32Bio@argotpartners.com

Media: David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/q32-bio-to-participate-in-the-25th-annual-needham-virtual-healthcare-conference-302736130.html

SOURCE Q32 Bio

FAQ

When will Q32 Bio (QTTB) present at the Needham Virtual Healthcare Conference?

Q32 Bio will present on April 15, 2026 at 12:45 p.m. ET. According to Q32 Bio, management will appear in a fireside chat format during the 25th Annual Needham Virtual Healthcare Conference to discuss corporate progress and strategy.

How can investors watch Q32 Bio's (QTTB) webcast from the April 15, 2026 event?

Investors can watch the live webcast on Q32 Bio's Events and Presentations page at www.q32bio.com. According to Q32 Bio, the webcast will stream during the scheduled fireside chat and is accessible without special registration beyond the company site.

Will Q32 Bio (QTTB) make a replay of the Needham conference presentation available?

Yes. According to Q32 Bio, an archived replay will be available for 90 days following the event. The replay will be posted on the company’s Events and Presentations page for on-demand viewing by investors and analysts.

What topics will Q32 Bio (QTTB) likely cover in its April 15, 2026 fireside chat?

The fireside chat will focus on clinical-stage development for alopecia areata and broader autoimmune programs. According to Q32 Bio, management will review clinical progress, strategic priorities, and next steps for the company's therapeutic pipeline.

Where can shareholders find materials or disclosures related to Q32 Bio's (QTTB) Needham presentation?

Shareholders can find presentation materials on the company’s Events and Presentations page at www.q32bio.com. According to Q32 Bio, any slides or supplemental disclosures used during the fireside chat will be posted on that page when available.